NasdaqGS:ANABBiotechs
Does AnaptysBio’s (ANAB) Buyback-Over-Equity Pivot Redefine Its Capital Discipline Narrative?
In March 2026, AnaptysBio announced plans to spin off First Tracks Biotherapeutics, manage existing drug collaborations with GSK and Vanda, operate with limited staff and expenses, and start with about US$140 million to US$145 million in net cash and investments, while also launching a US$100 million share repurchase program and withdrawing a US$100 million at-the-market equity offering.
The combination of a buyback authorization, canceled equity raise, and the addition of seasoned...